Treatment of Depression In Hemodialysis Patients

A Clinical Trial Comparing the Effect of Omega-3 with Serteraline and Placebo on Depression General Health Conditions Among Dialysis Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201201175113N2

Enrollment

Registered

2012-02-02

Start date

2012-02-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: End Stage Renal Disease. Condition 2: depression. Chronic kidney disease, stage 5 on dialysis Depressive episode, unspecified

Interventions

Intervention 1: group 1(treatmen group) : omega 3 1500 mg daily. Intervention 2: group intervention : sertralin 50-150 mg daily. Intervention 3: group 3 (control) : placebo.

Treatment - Drugs

Placebo

group 1(treatmen group) : omega 3 1500 mg daily

group intervention : sertralin 50-150 mg daily

group 3 (control) : placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion criteria: age more than18 ; patients with depression; patients on hemodialysis exclusion criteria: use of anti depressant drugs during last 3 months ; participation in related trials in last 3 months ; not cooperative patients ; not signing the consent.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Depression. Timepoint: time 0 and then weeks 4,8,12. Method of measurement: Hospital Depression Rating Scales test and SADS.	—

Secondary

Measure	Time frame
Hemoglobin level. Timepoint: At time 0 and at the end of study. Method of measurement: Laboratory evaluation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Mohammad Reza Khatami

Nephrology Research Center, Tehran University of Medical Sciences

khatamis@sina.tums.ac.ir+98 21 6119 2659

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026